Alembic Pharmaceuticals Ltd.'s shares surged over 12% to a nearly six-month high after the company received final approval from the US regulator for its new drug application to treat ovarian cancer and other ailments.
The US Food & Drug Administration approved the abbreviated new drug application for Doxorubicin Hydrochloride Liposome injection and single-dose vials, as per a regulatory filing.
The approved ANDA is therapeutically equivalent to those developed by Baxter Healthcare Corp.
Doxorubicin Hydrochloride Liposome injection is used for the treatment of ovarian cancer, AIDS-related Kaposi’s Sarcoma, and Multiple Myeloma. These products have an estimated market size of $29 million for the financial year ending March 2025, according to IQVIA.
Alembic Pharma has a cumulative total of 224 ANDA approvals (201 final approvals and 23 tentative approvals) from the USFDA.
Alembic Pharma Share Price Movement
Alembic Pharma share price advanced over 12.4% intraday to Rs 1,089 apiece and traded close to that level as of 9:55 a.m. That was the highest since Jan. 7. The benchmark NSE Nifty 50 was down 0.26%.
The stock has risen 16.5% in the last 12 months. The total traded volume so far in the day stood at 51 times its 30-day average. The relative strength index was at 72.
Out of 13 analysts tracking Alembic Pharma, eight have a 'buy' rating on the stock, four recommend a 'hold' and one suggests a 'sell', according to Bloomberg data. The average of 12-month analysts' price target of Rs 1,011 implies a potential downside of 4.4%.
RECOMMENDED FOR YOU
Trump Sets Sept 29 Deadline For J&J, Pfizer, Other Pharma Firms To Lower US Drug Prices
Jul 31, 2025
Sun Pharma, Lupin, Dr. Reddy's Recall Products In US market
Jul 27, 2025
Dr Reddy's Gets Form 483 With Seven Observations From USFDA After Inspection At Andhra Unit
Jul 18, 2025
AstraZeneca Pharma Gets CDSCO Nod For Import, Sale Of Bladder Cancer Drug
Jul 14, 2025
POPULAR